Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05336279
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC, Jinan, Jinan, China
The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: INS068 injection
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05336071
- Locations
- 🇨🇳
The Qian Foshan Hospital of Shandong Province, Jinan, Shandong, China
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
Phase 2
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: HR17031 injectionDrug: INS068 injectionDrug: SHR20004 injection
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 455
- Registration Number
- NCT05333835
- Locations
- 🇨🇳
Peking university People's Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis
Phase 3
Recruiting
- Conditions
- Non-radiographic Axial Spondyloarthritis
- Interventions
- Drug: SHR0302 placebo
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05324631
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Phase 3
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: TACE
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 425
- Registration Number
- NCT05320692
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.
Phase 2
Completed
- Conditions
- Pain
- Interventions
- Drug: Placebo tabletsDrug: HRS4800 tablets
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05318846
- Locations
- 🇨🇳
West China Hospital of Stomatology Sichuan University, Chengdu, Sichuan, China
A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT05318833
A Trial of HR17031 Injection With Renal Insufficiency
Phase 1
- Conditions
- Improved Glycemic Control in Patients With Type 2 Diabetes
- Interventions
- Drug: HR17031 injection
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05292495
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT05277168
- Locations
- 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States
🇺🇸LSU Health Sciences Center, New Orleans, Louisiana, United States
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
Phase 1
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05273775
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath